N@N

AtCor Medical Holdings Ltd.: AtCor Medical Expects 70% Sales Growth in 2009

_{//business-finance.news-articles.net/content/200 .. cor-medical-expects-70-sales-growth-in-2009.html}
^{Published in Business and Finance on Wednesday, May 20th 2009 at 8:13 GMT, Last Modified on 2009-05-20 08:14:35 by Market Wire}  

ITASCA, IL--(Marketwire - May 20, 2009) - AtCor Medical Holdings Limited (ASX: [ ACG ]), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has increased guidance for FY2009 sales revenue to AUS $11 million, up from AUS $10 million anticipated in February 2009. This represents an increase of 70% over FY2008 sales.

Duncan Ross, AtCor Medical President and CEO, said, "We are pleased with the progress made to date in a challenging economic environment. This improvement in our rate of growth demonstrates the increasing success of our sales strategy, along with some gains from the weaker Australian dollar. Of particular note is the expansion of the pharmaceutical trials market, which also provides further endorsement of the importance of central blood pressures in disease management."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company's SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects that cannot be detected with standard blood pressure monitoring. Central blood pressure has been found to be a superior predictor of cardiovascular events such as stroke, heart attack and kidney disease.

More than 1,900 SphygmoCor systems are currently in use worldwide at major medical and research institutions and in clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 400 peer-reviewed studies published in leading medical journals. AtCor has operations in the United States, Australia, and Europe. For further information, please visit our web site at [ www.atcormedical.com ].